and Signaling Glu1022.53-Mediated Early Conformational Changes in the Process of Light-Induced Green Cone modulator VU0486846 reduces neurogliosis in female Alzheimer's mice The association of GNB5 with Alzheimer disease of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models of Alzheimer's disease

contribute to the implementation of the guidelines, together improving translation from in vitro to disease-relevant

structural approach Mechanisms controlling haemolymph circulation under resting conditions in the chagas disease , and more Class B1 GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease

Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation

study in Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease

pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson’s disease , and Alzheimer’s disease.

protein-coupled receptor (GPCR) kinases (GRKs) are associated with the pathophysiology of Alzheimer's disease

sites of GPCRs for drug discovery Targeting mGluR group III for the treatment of neurodegenerative diseases Methods & Updates in GPCR Research Advancements in the use of xenopus oocytes for modelling neurological disease

intracellular protein complexes and solute carriers, are relevant to immunology indications and rare diseases

important drug targets, and numerous drugs that modulate GPCRs are already in clinical use for various diseases Drug repurposing: AI algorithms can screen existing drugs and repurpose them for GPCR-related diseases By analyzing drug-target interactions and disease pathways, AI can identify potential candidates that Towards a comprehensive understanding of GPCRs, ligands, diseases, and their associations: open-access

conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant

Neuroscience Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases

disaccharide sugar with known pro‐autophagy activity and effective in alleviating diverse inflammatory diseases

GPCRs in Cardiology, Endocrinology, and Taste Gender Differences in GRK2 in Cardiovascular Diseases and Manager Director of Molecular Pharmacology, Discovery Biology Staff Scientist/Senior Staff Scientist, Disease

Neisseria meningitidis is a Gram-negative opportunistic pathogen that is responsible for causing human diseases

protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's disease

cellulose-degrading enzymes Functional Water Channels Within the TSH Receptor - a new paradigm for TSH action with disease launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases

macrophages and monocytes, and play a critical role in neuroinflammatory conditions such as Alzheimer's disease

Molecular Endocrinology and Pharmacology Laboratory team who are investigating new ways to tackle the disease-inducing

numerous GPCRs have been studied for their impact on pathologic conditions, including cardiovascular diseases

knockdown regulates the expression and alternative splicing of genes associated with aphasia-related diseases ochraceus quorum sensing through the GprC-AcyA pathway Deciphering the genetic landscape of lumpy skin disease

Retinitis pigmentosa (RP) is a group of hereditary degenerative diseases affecting 1 of 4000 people worldwide

with the fact that dysregulation of compartmentalized GPCR signaling has been implicated in various diseases aberrant endosomal signaling by GPCRs has been linked to disorders such as cancer, neurodegenerative diseases Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases

Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor

effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia, a disease

(GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases

Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune System, and Western Diseases concept to metabolomics: New insights into pregnenolone function Molecular characterization of lumpy skin disease

Y2446.44 of the P5.50I3.40Y6.44 motif ultimately driving receptor activation: a) Route 1 - hydrogen bonding to Y2516.51 by CCL3 or CCL5; b) Route 2 - characterized by hydrogen bonding to E2837.39 by A4 of CCL3 receptors share a glutamine residue at the "toggle switch" position 6.48 and the disruption of a hydrogen-bond will pave the way for significant advancements in the development of therapeutics for a wide range of diseases